/PTLF

PTLF Stock - Petlife Pharmaceuticals, Inc.

Q: What is the analyst price target for PTLF?

Analyst price target information is not currently available for PTLF.

Q: What is PTLF's market cap?

Market capitalization information is not currently available for PTLF.

Healthcare|Drug Manufacturers - Specialty & Generic|OTC

$0.00+0.00%

+$0.00 (+0.00%) • Dec 19

GoAI Score

Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.

HOLD

Medium Confidence

Momentum

Momentum Score

Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.

Sentiment

Sentiment Score

Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).

Risk Score

Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.

Price Target

Average analyst price target from the last quarter. Shows expected upside/downside from current price.

+10.0%upside

Target: $0.00

AI Analysis PreviewPremium

Real-time AI-powered market analysis

Precise entry/exit price targets

Risk assessment & position sizing

Unlock GoAI Insights for PTLF

Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.

Buy/Sell Signals

94% win rate on Alpha signals

Deep Analysis

Institutional-grade thesis

Real-Time Alerts

SMS & push notifications

Risk Scoring

Multi-factor analysis

Free 14-day trial • No credit card required

Financial Statements

Revenue & Profitability Trend

FY2013

FY2014

FY2015

FY2016

FY2017

← Swipe to see more →

Revenue

Net Income (Profit)

Net Loss

Key Metrics

Market CapN/A

P/E RatioN/A

Beta3.91

52W High$0.00

52W Low$0.00

Avg VolumeN/A

Income Statement (Fiscal Year)

Metric	FY2017	FY2016	FY2015	FY2014	FY2013
Revenue	N/A	N/A	N/A	N/A	N/A
Gross Profit	N/A	N/A	$-220,733	$-60,079	$-221,516
Gross Margin	N/A	N/A	N/A	N/A	N/A
Operating Income	$-22,655,379	$-3,687,040	$-1,932,201	$-1,512,051	$-1,680,269
Net Income	$-23,256,850	$-3,687,040	$-1,932,201	$-1,512,051	$-1,160,764
Net Margin	N/A	N/A	N/A	N/A	N/A
EPS	$-0.33	$-0.40	$-0.17	$-0.20	$-11.95

Company Overview

Petlife Pharmaceuticals, Inc. engages in the research, development, sale, and support of drugs and nutraceuticals for pet cancer and autoimmune related diseases, such as arthritis in the United States. The company's principal product is Vitalzul that inhibits blood vessels formation in solid tumors. It is also developing Vitalzul as a prescription strength oral pharmaceutical, as well as a concentrated intravenous and injectable version for direct administration to a tumor. In addition, the company develops edible dog and cat treats. Petlife Pharmaceuticals, Inc. is based in Los Angeles, California.

Earnings History & Surprises

PTLF

Beat Rate

Last 0 quarters

Avg Surprise

+0%

EPS vs Estimate

Beats / Misses

0/0

Last 12 quarters

Latest EPS

$N/A

EPS Surprise History

Beat Estimate

Missed Estimate

Quarterly EPS Details

Period	Report Date	Estimated EPS	Actual EPS	Surprise	Result
Q3 2012	Jul 23, 2012	—	—	—	—
Q2 2012	Apr 23, 2012	—	—	—	—
Q1 2012	Jan 18, 2012	—	—	—	—
Q4 2011	Dec 1, 2011	—	—	—	—

Frequently Asked Questions about PTLF

What is PTLF's current stock price?

Petlife Pharmaceuticals, Inc. (PTLF) is currently trading at $0.00 per share. The stock has moved +0.00% today.

What is the analyst price target for PTLF?

No analyst price targets are currently available for this stock.

What sector is Petlife Pharmaceuticals, Inc. in?

Petlife Pharmaceuticals, Inc. operates in the Healthcare sector, specifically within the Drug Manufacturers - Specialty & Generic industry. The company is traded on the OTC exchange.

What is PTLF's market cap?

Petlife Pharmaceuticals, Inc. has a market capitalization of $0.00 billion, making it a small-cap company.

Does PTLF pay dividends?

No, Petlife Pharmaceuticals, Inc. does not currently pay a dividend to shareholders.